MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Methylene Blue Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Methylene Blue (methylthioninium chloride) is a phenothiazine dye and small-molecule mitochondrial enhancer. By redox-cycling inside mitochondria, it shuttles electrons from NADH to cytochrome c, raising cytochrome c oxidase activity, cerebral oxygen use, and ATP output, with antioxidant effects at low doses and pro-oxidant effects at high doses (a hormetic inverted-U) [1]. In humans, a single low oral dose (~280 mg) increased attention- and memory-related fMRI activity and improved memory retrieval by about 7% (PMID 27351678) [2]. It is also a potent MAO-A inhibitor and reduces methemoglobin back to hemoglobin, the basis for its FDA-approved IV antidote use. Most cognitive research uses single oral doses near 0.5-4 mg/kg; daily nootropic use is typically 5-30 mg. The real route is oral or IV — the subcutaneous reconstitution figures here are an educational measurement reference, and low-dose nootropic use is off-label.
Reconstitute: Add 2.5 mL bacteriostatic water → 20 mg/mL concentration.
Typical dose: 0.5-4 mg/kg orally (~5-30 mg/day low-dose nootropic)
Easy measuring: At 20 mg/mL, 1 unit = 0.01 mL = 0.2 mg (200 mcg) on a U-100 insulin syringe.
Storage: USP powder or tablets stored at room temperature, protected from light and moisture. Reconstituted or liquid solution refrigerated at 2-8 °C, kept in an amber/opaque vial because Methylene Blue is light-sensitive, and used within ~4 weeks.
Half-life: ~5-6.5 h terminal; oral bioavailability ~72%; dosed once daily (morning).
Route: Clinically oral (nootropic) or IV (methemoglobinemia); the subcutaneous figures here are an educational reconstitution reference only.
Status: FDA-approved IV drug for methemoglobinemia (Provayblue, 2016); low-dose oral nootropic use is off-label/research only.
About Methylene Blue
Methylene Blue (methylthioninium chloride) is a phenothiazine dye and small-molecule mitochondrial enhancer used at low doses as a nootropic and at higher intravenous doses as an FDA-approved antidote for methemoglobinemia [6][7]. It is a redox-active electron cycler: at low concentrations it accepts electrons from NADH and donates them directly to cytochrome c, boosting mitochondrial respiration and brain cytochrome c oxidase activity, while at high concentrations it flips to a pro-oxidant — the classic hormetic, inverted-U dose-response [1]. Clinically, and in every published cognitive trial, Methylene Blue is taken ORALLY (or given IV in hospital); the subcutaneous reconstitution figures below are an educational measurement reference only, not the real-world route.\n\nThe most-studied Methylene Blue dosage for cognition is a single low oral dose of roughly 0.5-4 mg/kg — about 260-280 mg in the controlled human fMRI and fear-extinction studies — while daily low-dose nootropic users typically take far less, on the order of 5-30 mg [2][4]. This guide models a 50 mg vial reconstituted with 2.5 mL of bacteriostatic water (20 mg/mL, 200 mcg per insulin-syringe unit) so example doses map cleanly onto a U-100 syringe: 5 mg ≈ 25 units, 10 mg ≈ 50 units, and 20 mg ≈ 100 units. Because the dose-response is hormetic, more is not better — staying inside the low window is the entire point [1].\n\nFrequency: Once daily, typically in the morning (terminal half-life ~5-6.5 h). Only pharmaceutical USP-grade material is appropriate for human reference; industrial dye grades carry heavy-metal contaminants. Low-dose oral nootropic use is off-label and is presented here for educational purposes only [6][7].
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2.5 mL of bacteriostatic water into a sterile syringe.
Inject the water slowly down the inner wall of the 50 mg Methylene Blue vial; do not aim the stream at the powder and avoid vigorous shaking. The solution will turn a deep, intense blue almost immediately.
Gently swirl or roll the vial until fully dissolved; the result is a 20 mg/mL concentration (200 mcg per insulin-syringe unit). Methylene Blue stains skin, clothing, and surfaces, so wipe spills promptly.
Store refrigerated at 2-8 °C in an opaque or foil-wrapped vial (it is light-sensitive), then draw the prescribed number of units per dose (5 mg ≈ 25 units, 10 mg ≈ 50 units, 20 mg ≈ 100 units).
Educational note: Methylene Blue is clinically taken ORALLY once daily (or given IV in hospital) — these subcutaneous reconstitution figures are a measurement reference only and not a validated delivery route.
Interactive Methylene Blue Syringe Calculator
Currently visualizing the 50 mg vial reconstituted with 2.5 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 50mg dry powder in 2.5mL water yields 20.00 mg/mL. To evaluate a 250mcg dose, pull to 1.3 units (1 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Microdose / tolerance check (week 1) | 5000 mcg (5 mg) | 25 units (0.25 mL) |
| Low-dose nootropic (common maintenance) | 10000 mcg (10 mg) | 50 units (0.50 mL) |
| Standard nootropic ceiling (hormetic upper edge) | 20000 mcg (20 mg) | 100 units (1.00 mL) |
Administration guidelines: Refer to guidelines | 2.5 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 50 mg vial.
Peptide Vials (Methylene Blue, 50 mg each):
- check8-week course at ~10 mg/day: about 12 vials (one 50 mg vial covers ~5 days).
- check12-week course at ~10 mg/day: about 17 vials.
- check16-week course at ~10 mg/day: about 23 vials.
- checkConservative ~5 mg/day microdosing roughly halves the vial count.
Insulin Syringes (U-100):
- check8 weeks, once daily: ~56 injections — one 100-count box.
- check12 weeks, once daily: ~84 injections — one 100-count box.
- check16 weeks, once daily: ~112 injections — two boxes (~120).
- checkOrder a few extra for priming/spoilage.
Bacteriostatic Water (30 mL bottles): Use 2.5 mL per vial for reconstitution.
- check8-week course (~12 vials): ~30 mL — one 30 mL bottle.
- check12-week course (~17 vials): ~43 mL — two 30 mL bottles.
- check16-week course (~23 vials): ~58 mL — two to three 30 mL bottles.
- checkOnce opened, refrigerate and observe the manufacturer's in-use window.
Alcohol Swabs:
- checkUse about 2 swabs per dose (vial stopper plus injection site).
- check8 weeks: ~112 swabs — one 200-count box.
- check12 weeks: ~168 swabs — one 200-count box.
- check16 weeks: ~224 swabs — two boxes.
Mechanism of Action (MOA)
Methylene Blue is a synthetic phenothiazine (thiazine) dye, methylthioninium chloride, with a molecular weight of about 319.85 g/mol. Its defining property is reversible redox cycling: it readily accepts electrons to become the colorless leucomethylene blue and gives them back to revert to the blue oxidized form. Inside mitochondria this lets it act as an alternative electron carrier, shuttling electrons from NADH (in the presence of complex I) and donating them directly to cytochrome c, effectively bypassing complexes I-III. The downstream effect is enhanced electron-transport-chain flux, increased cytochrome c oxidase (complex IV) activity, greater cerebral oxygen consumption, and higher ATP production [1][6].\n\nThis mechanism is intrinsically hormetic. At low concentrations Methylene Blue behaves as an antioxidant and metabolic enhancer; at high concentrations it self-oxidizes and generates reactive oxygen species, becoming a pro-oxidant that can impair the same mitochondria it otherwise supports. That inverted-U is why memory benefits peak around 1-4 mg/kg in animals and decline or reverse at higher doses [1]. In rats, a single 1 mg/kg dose raised brain cytochrome oxidase activity by ~30% at 24 hours [1].\n\nTwo other pharmacologies matter clinically. First, Methylene Blue is reduced by NADPH-dependent methemoglobin reductase to leucomethylene blue, which converts ferric (Fe3+) methemoglobin back to functional ferrous (Fe2+) hemoglobin — the basis for its FDA-approved use in methemoglobinemia [6]. Second, it is one of the most potent reversible monoamine oxidase-A inhibitors known, which underlies a serious serotonin-syndrome interaction with serotonergic drugs [7]. It also inhibits nitric oxide synthase and soluble guanylate cyclase, the rationale for off-label use in vasoplegic shock [6].\n\nPharmacokinetics: as an aqueous oral formulation, absolute bioavailability is high — about 72% (72.3 ± 23.9%) in a 16-subject phase I study — with peak plasma levels roughly 1-2 hours after an oral dose [3]. The terminal plasma half-life is approximately 5-6.5 hours, so a once-daily morning schedule is typical and the compound is substantially cleared within about 24 hours [3]. It is eliminated by both hepatic metabolism (to leucomethylene blue and demethylated metabolites) and renal excretion (roughly 40%), which characteristically tints urine blue-green; dosing should be reduced in significant renal impairment [6].\n\nReal-world route: Methylene Blue is taken orally for nootropic and most research use, and given intravenously in hospitals for methemoglobinemia. The subcutaneous reconstitution scheme on this page is an educational measurement convention used across this site, not a clinically validated delivery method. Only USP-grade material should ever be referenced for human use; industrial-grade dye can contain arsenic, aluminum, and other heavy-metal contaminants [1][6].
Clinical Trial Efficacy Highlights
- starRojas, Bruchey and Gonzalez-Lima (2012, Progress in Neurobiology) reviewed the metabolic mechanisms of methylene blue and reported that low post-training doses of 1-4 mg/kg reliably enhanced memory retention in rodents, that a single 1 mg/kg dose increased brain cytochrome oxidase activity by about 30% at 24 hours, and that the drug shows a hormetic dose-response with beneficial effects at low doses and opposite, impairing effects at high doses [1].
- starRodriguez and colleagues (2016, Radiology) ran a double-blind, placebo-controlled multimodal fMRI trial in 26 healthy adults: a single low oral dose of 280 mg methylene blue (~4 mg/kg) increased functional MRI activity during sustained-attention and short-term-memory tasks and produced roughly a 7% increase in correct memory-retrieval responses versus placebo [2].
- starGonzalez-Lima and Bruchey (2004, Learning & Memory) showed that 4 mg/kg methylene blue given after extinction training in rats reduced subsequent freezing (improved extinction-memory retention) and increased cytochrome oxidase activity in prefrontal cortical regions, directly linking the memory effect to enhanced brain energy metabolism [6].
- starTelch and colleagues (2014, American Journal of Psychiatry) found that post-session USP methylene blue after exposure therapy improved retention of fear extinction and contextual memory in claustrophobic adults who achieved low end-of-session fear, while it did not help (and could hinder) those with high residual fear — a clinical demonstration of state-dependent, hormetic-like effects [5].
- starZoellner, Telch, Foa, Gonzalez-Lima and colleagues (2017, Journal of Clinical Psychiatry) randomized PTSD patients to 260 mg methylene blue or placebo after brief daily imaginal exposure; the methylene blue group showed superior evaluator-rated response (number needed to treat = 7.5) and better quality of life (effect size d = 0.58), with a distinctive delayed-then-accelerated recovery trajectory [4].
- starWalter-Sack and colleagues (2009, European Journal of Clinical Pharmacology) characterized the pharmacokinetics in 16 healthy volunteers comparing 50 mg IV with 500 mg oral, establishing high oral absolute bioavailability of about 72% and a terminal plasma half-life near 5-6 hours, the basis for once-daily oral dosing [3].
- starFor its approved indication, methylene blue at 1 mg/kg IV (repeatable once) is a long-established, guideline-endorsed antidote that reduces ferric methemoglobin back to functional hemoglobin in acquired methemoglobinemia, the use for which Provayblue received FDA approval in 2016 [6][8].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningBlue-green discoloration of urine, and sometimes stool, saliva, sweat, or sclera, is expected and harmless; the dye also stains skin, clothing, and surfaces on contact [6].
- warningSerotonin syndrome is the most dangerous interaction: methylene blue is a potent reversible MAO-A inhibitor, and combining it with SSRIs, SNRIs, MAOIs, triptans, bupropion, buspirone, or other serotonergic agents has caused serious and even fatal reactions, prompting an FDA safety warning [7].
- warningG6PD deficiency is a contraindication — at clinical doses methylene blue can precipitate severe hemolytic anemia in these individuals, so screening is advised before use, especially in people of African, Mediterranean, or South/Southeast Asian ancestry [6].
- warningThe dose-response is hormetic: above roughly 4 mg/kg the compound becomes a pro-oxidant, and high intravenous doses (≥7 mg/kg) can cause nausea, dyspnea, chest pain, tremor, confusion, hypertension, and paradoxical methemoglobinemia [6].
- warningLower-grade oral effects include gastrointestinal upset, mild bladder irritation or dysuria, headache, dizziness, and a transient metallic taste, particularly at the higher end of the dosing range.
- warningPregnancy is a contraindication; high-dose and intra-amniotic exposure has been linked to fetal harm, intestinal atresia, and neonatal hyperbilirubinemia [6].
- warningMethylene Blue interferes with pulse oximetry (causing transiently falsely low SpO2 readings) and can affect some laboratory colorimetric assays [6].
- warningRegulatory/research status: methylene blue is FDA-approved only as an IV drug (Provayblue, initial approval 2016) for acquired methemoglobinemia; low-dose oral nootropic use is off-label and not FDA-approved, only pharmaceutical USP-grade material is appropriate for human reference, and the subcutaneous route modeled here is educational only [6][7].
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Methylene Blue dosage?expand_more
In controlled human cognitive trials the typical Methylene Blue dosage is a single low oral dose of roughly 0.5-4 mg/kg — about 260-280 mg in the published fMRI and fear-extinction studies. Daily low-dose nootropic users generally take much less, on the order of 5-30 mg per day. The response is hormetic (inverted-U), so doses above about 4 mg/kg can reverse the benefit and become pro-oxidant; more is not better.
Is Methylene Blue FDA approved?expand_more
Partly. Methylene Blue is FDA-approved as an intravenous drug — Provayblue, initial U.S. approval 2016 — for the treatment of acquired methemoglobinemia, dosed at 1 mg/kg IV. Low-dose oral use as a nootropic or mitochondrial enhancer is off-label and not FDA-approved, and only pharmaceutical USP-grade material is appropriate for any human reference.
What is the half-life of Methylene Blue?expand_more
Methylene Blue has a terminal plasma half-life of approximately 5-6.5 hours and an oral absolute bioavailability of about 72%, with peak levels roughly 1-2 hours after an oral dose. It is substantially cleared within about 24 hours and is eliminated by both liver metabolism and renal excretion (about 40%), which tints the urine blue-green. This short half-life is why it is dosed once daily, usually in the morning.
How is Methylene Blue actually taken, and how do you reconstitute it?expand_more
Clinically and for nootropic research it is taken orally (as USP solution drops or capsules), or given intravenously in hospitals for methemoglobinemia — it is not normally injected subcutaneously. The reconstitution figures on this page are an educational measurement reference: a 50 mg vial mixed with 2.5 mL of bacteriostatic water yields 20 mg/mL (200 mcg per insulin-syringe unit), so 5 mg ≈ 25 units, 10 mg ≈ 50 units, and 20 mg ≈ 100 units. Keep the solution refrigerated and protected from light.
What are the main Methylene Blue side effects and interactions?expand_more
Expect harmless blue-green urine and possible staining of skin and clothing. The most serious risk is serotonin syndrome, because Methylene Blue is a potent MAO-A inhibitor that should not be combined with SSRIs, SNRIs, MAOIs, triptans, or bupropion. It is contraindicated in G6PD deficiency (hemolysis risk) and pregnancy, can cause pro-oxidant toxicity and methemoglobinemia at high doses, and interferes with pulse oximetry readings.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Methylene Blue, plus the universal dosing calculator.
Academic References & Study Citations
Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol. 2012;96(1):32-45. View Scientific Paper →
Rodriguez P, Zhou W, Barrett DW, et al. Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. Radiology. 2016;281(2):516-526. View Scientific Paper →
Walter-Sack I, Rengelshausen J, Oberwittler H, et al. High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol. 2009;65(2):179-189. View Scientific Paper →
Zoellner LA, Telch M, Foa EB, et al. Enhancing Extinction Learning in Posttraumatic Stress Disorder With Brief Daily Imaginal Exposure and Methylene Blue: A Randomized Controlled Trial. J Clin Psychiatry. 2017;78(7):e782-e789. View Scientific Paper →
Telch MJ, Bruchey AK, Rosenfield D, et al. Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. Am J Psychiatry. 2014;171(10):1091-1098. View Scientific Paper →
Ginimuge PR, Jyothi SD. Methylene Blue. In: StatPearls. Treasure Island (FL): StatPearls Publishing; updated 2023. View Scientific Paper →
Bužga M, Machytka E, Dvořáčková E, et al. Methylene blue: a controversial diagnostic acid and medication? Toxicol Res (Camb). 2022;11(5):711-717. View Scientific Paper →
Gonzalez-Lima F, Bruchey AK. Extinction memory improvement by the metabolic enhancer methylene blue. Learn Mem. 2004;11(5):633-640. View Scientific Paper →
Drugs.com. Methylene Blue Dosage Guide + Max Dose, Adjustments (IV use for methemoglobinemia, 1 mg/kg). View Scientific Paper →